文拉法辛缓释剂与氯米帕明治疗躯体化障碍的疗效比较  

A Comparison between Venlafaxine XR and Chlorimipramine in the Treatment of Somatization Disorder

作　　者：钱建军[1] 严伟良[1] 徐宝昌[1] 

机构地区：[1]浙江省绍兴市第七人民医院心理科,312000

出　　处：《医药导报》2009年第3期321-322,共2页Herald of Medicine

摘　　要：目的比较文拉法辛缓释剂与氯米帕明治疗躯体化障碍的疗效和不良反应。方法躯体化障碍患者130例,随机分为两组。治疗组64例,对照组66例,分别用文拉法辛缓释剂与氯米帕明治疗8周。用90项症状清单(SCL-90)中的躯体化、抑郁和焦虑3个因子总分以及临床疗效总评量表-病情严重程度(CGI-SI)评定症状变化,用不同减分率评定疗效。用不良反应量表(TESS)评定药物不良反应。结果治疗组痊愈率61.8%,总有效率89.1%;对照组痊愈率44.4%,总有效率75.9%,两组疗效比较差异有显著性(P<0.05)。各时点TESS测评组间比较,差异均有显著性(P<0.05)。结论文拉法辛缓释剂治疗躯体化障碍疗效确切,不良反应较小。Objective To compare the therapeutic and side effects between venlafaxine XR and chlorimipramine in the treatment of somatization disorder. Methods One hundred and thrity patients with somatization disorder were randomized into two groups, which were treated with venlafaxine XR or chlorimipramine respectively for 8 weeks. The symptomatic changes were evaluated using the total score of somatization, depression and anxiety as described in Symptom Checklist 90 （SCL-90） and Clinical Global Impression-severity of illness（CGI-SI）. The therapeutic effect was assessed using various subtraction rates, and drug-related adverse reactions were evaluated using the Treatment Emergent Symptom Scale （TESS）. Results The recovery rate was 61.8% in the venlafaxine XR treatment group and 44.4% in the chlorimipramine treatment group, and the total effective rate was 89.1% and 75.9%, respectively. Tile difference in the efficacy between two treatments was significant （ P 〈 0.05 ）. TESS tests revealed that there were significant differences between two groups at various time points （ P 〈 0.05 ）. Conclusion Venlafaxine XR is effective in the treatment of somatization disorders, although has few adverse reactions.

关 键 词：文拉法辛缓释剂 氯米帕明 躯体化障碍 

分 类 号：R971.4[医药卫生—药品] R749.2[医药卫生—药学]